SkinBioTherapeutics
SBTX · AIM · Health Care · mcap £16m today, £31m on 27 Jul
- Holder at 25–30 %, 12 May: TR-1: Standard form for notification of major holdings RNS
- Keeps buying, 27 Jul: 3 notices since 12 May: TR-1: Standard form for notification of major holdings RNS
- Watch: next signal would be “30 % crossed or offer” – Holding of 30 % or more, or a Rule 9 / mandatory offer, within 365 days.
AI summary with checked claims arrives with the nightly run. These lines are the matched extracts.
All announcements
-
22 Sep 26Trading Statement
22 September 2026 – SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health announces that both the former interim CEO, Rachel Parsonage and former acting Chair, Alyson Levett have agreed to make their roles permanent.
RNS 9783213 ↗ -
24 Aug 26Appointment of Interim CFO New CFO
24 August 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has appointed Anita Slater as Interim CFO (non-Board) for an initial six-month term.
RNS 9735277 ↗ -
27 Jul 26SIGNAL 2 Keeps buying
TR-1: Standard form for notification of major holdings
Holding(s) in Company · RNS 9687759 ↗ -
21 Jul 26Holding(s) in Company Holder at 25–30 %
TR-1: Standard form for notification of major holdings
RNS 9678473 ↗ -
29 Jun 26IMC Presentation Statement
29 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, will be presenting to shareholders at 09.00 BST today, Monday 29 June 2026 on the Investor Meet Company platform (see details below).
RNS 9640580 ↗ -
25 Jun 26Directorate Change New CFO
25 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that Emily Bertram, Chief Financial Officer, has decided to leave the business on 30 June 2026.
RNS 9637172 ↗ -
23 Jun 26Notice of Investor Presentation
23 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life sciences business focused on skin health, will be presenting to shareholders at 9am BST on Monday 29 June 2026.
RNS 9632390 ↗ -
08 Jun 26Restoration - SkinBioTherapeutics PLC
Trading on AIM for the under-mentioned securities was temporarily suspended.
RNS 9606127 ↗ -
08 Jun 26Half-year Results (HY26) and Restated FY25 Results
Unaudited Half Year Results and Restated unaudited FY25 Results
RNS 9605350 ↗ -
28 May 26Update on Investigation, Interims and Auditors
28 May 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that its investigation into, inter alia, the financial statements for the year ended 30 June 2025 is complete.
RNS 9588707 ↗ -
12 May 26SIGNAL 1 Holder at 25–30 %
TR-1: Standard form for notification of major holdings
Holding(s) in Company · RNS 9564004 ↗ -
29 Apr 26Update on the FRP Investigation
29 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that FRP Advisory is in the final stages of its forensic investigation and is expected to provide its report to the Board in the...
RNS 9544781 ↗ -
01 Apr 26Suspension - Skinbiotherapeutics plc
Trading on AIM for the under-mentioned securities has been temporarily suspended from 01/04/2026 7:30am, pending publication of the Company's half-yearly report.
RNS 9502733 ↗ -
01 Apr 26Statement re. Suspension
1 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that trading in the Company's ordinary shares will be suspended with effect from 7.30am today as a consequence of the Company not...
RNS 9501709 ↗ -
20 Mar 26Update On Board Investigation and Interims Date
· HY26 results to be delayed until Board Investigation is complete
RNS 9484791 ↗ -
09 Mar 26Appointment of the Interim CEO to the Board New CEO
Appointment of the Interim CEO to the SBTX Board of Directors
RNS 9463579 ↗ -
02 Mar 26Appointment of Interim CEO New CEO
2 March 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has appointed Rachel Parsonage as Interim CEO for a period of six months, during which time she will also serve as a member of the Board.
RNS 9452201 ↗ -
20 Feb 26Independent Investigation Appointment
20 February 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that it has appointed its new Non-Executive Director and Chair of the Audit Committee, Alyson Levett, to oversee the...
RNS 9439288 ↗ -
16 Feb 26Update on Board Investigation
· Very recent new information has led the Board to seek the reversal of all accrued royalty income from the audited FY25 revenues
RNS 9431388 ↗ -
13 Feb 26Resignation of CEO New CEO
Resignation of CEO And Changes in Leadership Responsibilities
RNS 9429131 ↗ -
05 Jan 26Directorate Change
5 January 2026 - SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces the appointment of Alyson Levett as new non-executive director and Chair of the Audit Committee and the promotion of Emily Bertram to Chief...
RNS 9332326 ↗ -
18 Dec 25Reconfirmation of Market Guidance and AGM Q&A
Reconfirmation of Market Guidance and AGM Shareholder Information
RNS 9305029 ↗ -
05 Dec 25Final Results
5 December 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, reports its full year results for the 12 months ended 30 June 2025.
RNS 9277381 ↗ -
14 Oct 25Directorate Change
14 October 2025 - the Board of Directors of SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces that Simon Hewitson, an Executive Director on the Board and Chief Operating Officer of the Group, will be stepping away...
RNS 9168749 ↗ -
06 Oct 25Superdrug first phase of store locations
Superdrug first phase of store locations for AxisBiotix™ launch in the UK
RNS 9151409 ↗
Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.